Distinctions between homogeneous bulk cancer cell tumors vs. Cancer Stem cell driven tumors by Pr. Clarke

Anti PSA antibody (GTX100054)

Professor Alan Clarke, (Director of the European Cancer Stem Cell Research Institute) has recently given an overview of how Cancer Stem cell tumors differ from the conventional “homogenous bulk cancer cells” concept.

If the notions of Cancer Stem Cells and the existence of a cellular hierachy in tumors start to be described, Pr. Clarke introduces the new implications and scientific and therapeutical challenges in cancer studies (basic research, personalised medicine, biomarker discovery, new therapeutic target identification…)

To know more: Research shows differences in cancer stem cells by Professor Alan Clarke

Philippe Fixe, PhD
Written by Philippe Fixe, PhD
Philippe Fixe is Marketing Director at tebu-bio, passionate about innovation and R&D in Life sciences, Biotechnology, Medical research, Drug discovery, and also a keen photographer.